CAPR EBITDA Margin
Capricor Therapeutics Inc · EBITDA Margin
CAPR EBITDA Margin
Latest reported-720.79%period ending
CAPR TTM EBITDA Margin (-60.42% → -720.79%)
TTM ebitda margin
High-resolution chart · PNG
CAPR ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -720.7889% | |
| -510.352% | |
| -308.493% | |
| -175.3083% | |
| -141.0173% | |
| -98.2392% | |
| -85.4046% | |
| -84.2744% | |
| -201.3789% | |
| -300.4922% | |
| -510.9808% | |
| -1,116.4706% | |
| -1,700.7758% | |
| -10,976.2943% | |
| -8,079.2771% | |
| -5,884.0187% | |
| -5,576.9286% | |
| -10,027.3309% | |
| -4,366.1821% | |
| -2,286.1576% | |
| -1,426.5464% | |
| -741.8314% | |
| -752.4823% | |
| -652.616% | |
| -788.0317% | |
| -931.2856% | |
| -904.8934% | |
| 50.1332% | |
| 183.4785% | |
| 166.3938% | |
| 135.7655% | |
| -481.0869% | |
| -506.7436% | |
| -559.9095% | |
| -574.7801% | |
| -503.3984% | |
| -406.4641% | |
| -364.1418% | |
| -330.9259% | |
| -260.141% | |
| -221.7417% | |
| -180.7641% | |
| -131.9346% | |
| -0.2876% | |
| -0.2887% | |
| -0.2922% | |
| -0.2979% | |
| -1,538.072% | |
| -519.1473% | |
| -324.462% | |
| -221.8939% | |
| -288.5588% | |
| -261.797% | |
| -287.2959% | |
| -360.1329% | |
| -367.2131% | |
| -1,423.1214% | |
| -14,111.4211% | |
| -10,353.6761% | |
| -8,233.176% | |
| -5,891.2217% | |
| -21,443.7372% | |
| -495.5586% | |
| -682.9212% | |
| -739.8352% | |
| -665.7509% | |
| -1,384,550% | |
| -154.8328% | |
| -146.6301% | |
| -113.3403% | |
| -60.4163% |